REGENXBIO, Inc. RGNX 深 滬
等待開盤 05-20 09:30:00 美东时间
5.63
-0.020
-0.35%
華盛通- 最 高5.71
- 今 開5.70
- 成交量 78.93万股
- 最 低 5.50
- 昨 收 5.65
- 總市值 2.91亿
- 52周最高 16.19
- 市盈率 靜 --
- 換手率 1.53%
- 52周最低 5.455
- 委 比 -41.55%
- 總股本 5169.76万
- 歷史最高 85.10
- 量 比 0.32
- 振 幅 3.72%
- 歷史最低 5.035
- 每 手 1
- 風險率 2.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多电话会总结 ｜ Regenxbio(RGNX)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据提供的业绩会实录，我需要指出一个重要问题： **财务信息缺失说明：** 该业绩会实录主要聚焦于RGX-202药物的临床试验数据和监管进展，**未包含具体的财务业绩数据**。实录中仅简单提及"REGENXBIO continues executing against our mission to deliver multiple first and best-in-class gene therapies"以及2026年第一季度财务结果已发布，但**未披露任何具体的财务指标**。 **基于现有信息的有限财务概况：**</p> <p>•
05-19 12:16
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
Barclays Maintains Overweight on Regenxbio, Lowers Price Target to $12
Barclays analyst Gena Wang maintains Regenxbio (NASDAQ:RGNX) with a Overweight and lowers the price target from $37 to $12.
05-15 22:09
REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval
REGENXBIO reports positive Phase 3 Duchenne trial data as RGX-202 met its primary endpoint with strong safety results.
05-15 00:03
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Alpha Compute (NASDAQ:ALP) shares increased by 71.3% to $0.46 during T...
05-14 20:05
Regenxbio's Shares Topline And Interim Functional Data From Pivotal Phase 3 Portion Of Phase 1/2/3 Affinity Duchenne Trial Of RGX-202 For Duchenne Muscular Dystrophy, Meeting The Primary Endpoint With High Statistical Significance
REGENXBIO Inc. (NASDAQ:RGNX) announced positive topline and interim functional data from the pivotal Phase III portion of the Phase I/II/III AFFINITY DUCHENNE® trial of RGX-202, a potential best-in-class gene
05-14 19:12
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals
Regenxbio releases new Duchenne trial data showing improved motor function and stable heart measures in early-stage patients.
03-12 02:19
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
